Group One Trading
GLUE icon

Group One Trading’s Monte Rosa Therapeutics GLUE Stock Holding History

Group One Trading’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,398
Closed -$24.1K – 8173
2025
Q1 		$25K Buy
+5,398
New +$33.1K ﹤0.01% 5667

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Group One Trading's GLUE Position: Q2 2025 in Review

Group One Trading sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 5,398 shares — an estimated $24.1K sold.

Group One Trading first reported a position in GLUE in Q1 2025 and held it in 1 quarter. The position peaked at $25K in Q1 2025. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

  • Group One Trading reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Group One Trading sold 5,398 Monte Rosa Therapeutics shares in Q2 2025, an estimated $24.1K.
  • Group One Trading first reported a position in Monte Rosa Therapeutics in Q1 2025 and held it in 1 quarter.
  • Group One Trading's Monte Rosa Therapeutics position peaked at $25K in Q1 2025.
  • 116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Group One Trading's 13F filing for Q2 2025, filed 14 Aug 2025.